Haemonetics Corporation (HAE), a leader in medical technology focused on enhancing patient outcomes, announced on Tuesday the completion of the sale of its whole blood assets to GVS S.p.A. GVS is a company specializing in filter solutions for healthcare and life sciences sectors.
This strategic agreement involves the divestiture of Haemonetics' comprehensive range of whole blood collection, processing, and filtration solutions. Included in the deal are the corporation's manufacturing plant in Covina, California, along with related equipment and assets at its Tijuana, Mexico site.
The transaction, valued at up to $67.8 million, includes an upfront payment of $45.3 million, with potential additional earn-outs totaling up to $22.5 million over the next four years. Haemonetics intends to utilize the proceeds from this transaction for general corporate purposes and to fuel further investments in its growth initiatives.
Notably, Haemonetics' Blood Center business will continue its full line of apheresis solutions, which encompass devices and disposable kits for automated blood collection.
As of now, HAE's shares are trading at $78.83, reflecting a decrease of 0.73 percent, or $0.58, on the New York Stock Exchange.
